Login to Your Account



Clinic Roundup


Tuesday, August 21, 2012
• Juventas Therapeutics Inc., of Cleveland, treated the first patient in its Phase II STOP-HF trial. The 90-patient, placebo-controlled, randomized, double-blind study is evaluating the safety and efficacy of JVS-100 in late-stage heart failure.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription